Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7394037 | 0.74 | LTA4H (0.40) | FGFR1CYP11B1CYP11B2 | |
| SCHEMBL9231437 | 0.74 | FGFR1 (0.56) | FGFR1HPGDNPC1RAB9AMAPT | |
| SCHEMBL7213819 | 0.72 | GRM5 (0.34) | NPC1RAB9ACYP11B1CYP11B2 | |
| SCHEMBL2794301 | 0.72 | HTT (0.48) | FGFR1HPGDCYP11B1CYP11B2 | |
| SCHEMBL3852750 | 0.72 | NPC1 (0.47) | FGFR1HPGDNPC1RAB9ATP53 | |
| SCHEMBL28738388 | 0.71 | NPC1 (0.39) | FGFR1HPGDNPC1RAB9ASRC | |
| SCHEMBL3855438 | 0.71 | FGFR1 (0.56) | FGFR1HPGDNPC1RAB9ACYP11B1 | |
| SCHEMBL1878053 | 0.71 | FGFR1 (0.56) | FGFR1HPGDNPC1RAB9ASRC | |
| SCHEMBL3042174 | 0.71 | NPC1 (0.41) | FGFR1HPGDNPC1RAB9ASRC | |
| SCHEMBL9049120 | 0.70 | MAPT (0.38) | FGFR1HPGDNPC1RAB9ACYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610701-B2 | For therapy and prophylaxis of blood coagulation and cardiovascular disorders | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| US-6610692-B1 | Anticoagulants | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020193398-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-12-19 | — | — | US | disclosed |
| EP-1124822-A4 | THROMBIN INHIBITORS | MERCK & CO INC (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1124822-A1 | THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193398-A1 | Thrombin inhibitors | F2, F3, TFPI | FGFR1 3124/4885HPGD 2066/4885NPC1 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.